Modifying clinical practices to manage influenza in children effectively.
Identifieur interne : 001240 ( Main/Exploration ); précédent : 001239; suivant : 001241Modifying clinical practices to manage influenza in children effectively.
Auteurs : William Paul Glezen [États-Unis]Source :
- The Pediatric infectious disease journal [ 0891-3668 ] ; 2008.
Descripteurs français
- KwdFr :
- Adolescent, Animaux, Antiviraux (usage thérapeutique), Chimioprévention, Enfant, Enfant d'âge préscolaire, Grippe humaine (), Grippe humaine (diagnostic), Grippe humaine (mortalité), Grippe humaine (traitement médicamenteux), Hospitalisation (), Humains, Nourrisson, Nouveau-né, Oséltamivir (usage thérapeutique), Sialidase (antagonistes et inhibiteurs), Sous-type H1N1 du virus de la grippe A (), Sous-type H2N2 du virus de la grippe A (), Sous-type H5N1 du virus de la grippe A (), Vaccins antigrippaux (administration et posologie), Virus influenza B (), Zanamivir (usage thérapeutique).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- antagonistes et inhibiteurs : Sialidase.
- diagnostic : Grippe humaine.
- mortalité : Grippe humaine.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux, Oséltamivir, Zanamivir.
- Adolescent, Animaux, Chimioprévention, Enfant, Enfant d'âge préscolaire, Grippe humaine, Hospitalisation, Humains, Nourrisson, Nouveau-né, Sous-type H1N1 du virus de la grippe A, Sous-type H2N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Virus influenza B.
English descriptors
- KwdEn :
- Adolescent, Animals, Antiviral Agents (therapeutic use), Chemoprevention, Child, Child, Preschool, Hospitalization (statistics & numerical data), Humans, Infant, Infant, Newborn, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H2N2 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (drug effects), Influenza B virus (drug effects), Influenza Vaccines (administration & dosage), Influenza, Human (diagnosis), Influenza, Human (drug therapy), Influenza, Human (mortality), Influenza, Human (prevention & control), Neuraminidase (antagonists & inhibitors), Oseltamivir (therapeutic use), Zanamivir (therapeutic use).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Oseltamivir, Zanamivir.
- diagnosis : Influenza, Human.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza B virus.
- drug therapy : Influenza, Human.
- mortality : Influenza, Human.
- prevention & control : Influenza, Human.
- statistics & numerical data : Hospitalization.
- Adolescent, Animals, Chemoprevention, Child, Child, Preschool, Humans, Infant, Infant, Newborn.
Abstract
Children less than 5 years of age are at increased risk of morbidity from influenza infection compared with older children and adults aged 18-54 years. Although much of the disease burden can be prevented by annual vaccination, the misperception that influenza does not result in serious illness in children, including schoolchildren, contributes to ongoing low vaccination rates. In conjunction with community surveillance of influenza activity, rapid diagnostic tests can help identify influenza patients who may benefit from initiation of antiviral therapy. Antiviral therapy is most effective when started within at least 48 hours of the onset of symptoms, the earlier the better. The neuraminidase inhibitors oseltamivir and zanamivir are safe and effective as first-line treatments and prophylaxis for influenza in children. These agents have been shown to decrease symptoms and shorten the duration of illness, as well as to curb the spread of influenza infection. The neuraminidase inhibitors also have shown efficacy against influenza B infection and exhibit less viral resistance than the older adamantane antiviral class.
DOI: 10.1097/INF.0b013e31816d9299
PubMed: 18664986
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000251
- to stream PubMed, to step Curation: 000251
- to stream PubMed, to step Checkpoint: 000231
- to stream Ncbi, to step Merge: 000308
- to stream Ncbi, to step Curation: 000308
- to stream Ncbi, to step Checkpoint: 000308
- to stream Main, to step Merge: 001251
- to stream Main, to step Curation: 001240
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modifying clinical practices to manage influenza in children effectively.</title><author><name sortKey="Glezen, William Paul" sort="Glezen, William Paul" uniqKey="Glezen W" first="William Paul" last="Glezen">William Paul Glezen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM-280, Houston, TX 77030, USA. wglezen@bcm.tmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM-280, Houston, TX 77030</wicri:regionArea><wicri:noRegion>TX 77030</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18664986</idno><idno type="pmid">18664986</idno><idno type="doi">10.1097/INF.0b013e31816d9299</idno><idno type="wicri:Area/PubMed/Corpus">000251</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000251</idno><idno type="wicri:Area/PubMed/Curation">000251</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000251</idno><idno type="wicri:Area/PubMed/Checkpoint">000231</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000231</idno><idno type="wicri:Area/Ncbi/Merge">000308</idno><idno type="wicri:Area/Ncbi/Curation">000308</idno><idno type="wicri:Area/Ncbi/Checkpoint">000308</idno><idno type="wicri:doubleKey">0891-3668:2008:Glezen W:modifying:clinical:practices</idno><idno type="wicri:Area/Main/Merge">001251</idno><idno type="wicri:Area/Main/Curation">001240</idno><idno type="wicri:Area/Main/Exploration">001240</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modifying clinical practices to manage influenza in children effectively.</title><author><name sortKey="Glezen, William Paul" sort="Glezen, William Paul" uniqKey="Glezen W" first="William Paul" last="Glezen">William Paul Glezen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM-280, Houston, TX 77030, USA. wglezen@bcm.tmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM-280, Houston, TX 77030</wicri:regionArea><wicri:noRegion>TX 77030</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Pediatric infectious disease journal</title><idno type="ISSN">0891-3668</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Chemoprevention</term><term>Child</term><term>Child, Preschool</term><term>Hospitalization (statistics & numerical data)</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H2N2 Subtype (drug effects)</term><term>Influenza A Virus, H5N1 Subtype (drug effects)</term><term>Influenza B virus (drug effects)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (diagnosis)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (prevention & control)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (therapeutic use)</term><term>Zanamivir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Chimioprévention</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Grippe humaine ()</term><term>Grippe humaine (diagnostic)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Hospitalisation ()</term><term>Humains</term><term>Nourrisson</term><term>Nouveau-né</term><term>Oséltamivir (usage thérapeutique)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sous-type H2N2 du virus de la grippe A ()</term><term>Sous-type H5N1 du virus de la grippe A ()</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Virus influenza B ()</term><term>Zanamivir (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Animals</term><term>Chemoprevention</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Animaux</term><term>Chimioprévention</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Grippe humaine</term><term>Hospitalisation</term><term>Humains</term><term>Nourrisson</term><term>Nouveau-né</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Virus influenza B</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Children less than 5 years of age are at increased risk of morbidity from influenza infection compared with older children and adults aged 18-54 years. Although much of the disease burden can be prevented by annual vaccination, the misperception that influenza does not result in serious illness in children, including schoolchildren, contributes to ongoing low vaccination rates. In conjunction with community surveillance of influenza activity, rapid diagnostic tests can help identify influenza patients who may benefit from initiation of antiviral therapy. Antiviral therapy is most effective when started within at least 48 hours of the onset of symptoms, the earlier the better. The neuraminidase inhibitors oseltamivir and zanamivir are safe and effective as first-line treatments and prophylaxis for influenza in children. These agents have been shown to decrease symptoms and shorten the duration of illness, as well as to curb the spread of influenza infection. The neuraminidase inhibitors also have shown efficacy against influenza B infection and exhibit less viral resistance than the older adamantane antiviral class.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Glezen, William Paul" sort="Glezen, William Paul" uniqKey="Glezen W" first="William Paul" last="Glezen">William Paul Glezen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001240 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001240 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18664986
|texte= Modifying clinical practices to manage influenza in children effectively.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18664986" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |